Gupta Aashray, Erridge Simon, Graf Vivian, Kelada Monica, Bapir Lara, Jesuraj Naveen, Warner-Levy John, Clarke Evonne, McLachlan Katy, Coomber Ross, Rucker James J, Platt Michael W, Sodergren Mikael H
Medical Cannabis Research Group, Imperial College London, London, UK.
Department of Medicine, Curaleaf Clinic, London, UK.
Expert Rev Gastroenterol Hepatol. 2024 Dec;18(12):829-838. doi: 10.1080/17474124.2024.2443574. Epub 2025 Jan 9.
Treatments for inflammatory bowel disease (IBD) remain limited, and cannabis-based medicinal products (CBMPs) provide promise in addressing inflammation and pain. However, long-term data on CBMP efficacy in IBD are scarce. This study examines health-related quality of life (HRQoL) changes in IBD patients treated with CBMPs.
Patients with IBD were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in the short IBD questionnaire (SIBDQ), EQ-5D-5L, single-item sleep quality scale (SQS), and generalized anxiety disorder-7 (GAD-7), from baseline to 18-months after CBMP treatment started. Secondary outcomes were adverse event prevalence.
Analysis of 116 patients with IBD included 94 males (81.03%) with a mean age of 39.52 ± 9.12 years. There were improvements in the SIBDQ, GAD-7, SQS, and EQ-5D-5L Index ( < 0.001). At 18-months, 30 (25.86%) patients achieved a minimal clinically important difference (MCID) in the SIBDQ. Patients with severe baseline anxiety and above-median THC doses were more likely to achieve this MCID ( < 0.050). Twenty (17.24%) patients reported 155 (133.62%) adverse events.
CBMP treatment was associated with improvement in IBD-specific outcomes in patients and general HRQoL over 18-months. However, causation cannot be inferred. Hence, randomized controlled trials are still required.
炎症性肠病（IBD）的治疗方法仍然有限，而基于大麻的药用产品（CBMPs）在解决炎症和疼痛方面展现出前景。然而，关于CBMPs对IBD疗效的长期数据稀缺。本研究调查了接受CBMPs治疗的IBD患者与健康相关的生活质量（HRQoL）变化。
从英国医用大麻登记处识别出IBD患者。主要结局指标为从基线到CBMP治疗开始后18个月，短IBD问卷（SIBDQ）、EQ-5D-5L、单项睡眠质量量表（SQS）和广泛性焦虑障碍-7（GAD-7）的变化。次要结局指标为不良事件发生率。
对116例IBD患者的分析包括94例男性（81.03%），平均年龄为39.52±9.12岁。SIBDQ、GAD-7、SQS和EQ-5D-5L指数均有改善（P<0.001）。在18个月时，30例（25.86%）患者在SIBDQ中达到最小临床重要差异（MCID）。基线焦虑严重且THC剂量高于中位数的患者更有可能达到这一MCID（P<0.050）。20例（17.24%）患者报告了155起（133.62%）不良事件。
CBMP治疗与患者IBD特异性结局及18个月内总体HRQoL的改善相关。然而，无法推断因果关系。因此，仍需要进行随机对照试验。
